Skip to main content

Table 1 Summary of treatment conditions on BV-2 and IMA2.1 cells and their effects on VACV infection

From: Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps

Treatment condition

BV-2

IMA2.1

BV-2

IMA2.1

Virus progenya

VACV-mediated cell deathb

M2 phenotype

 w/o

+

0

+

 IL-4

+

nt

+

M1 phenotype

 IFN-γ

 IFN-γ + LPS

 LPS

  1. nt not tested, w/o without stimulation.
  2. aVirus progeny (24 and 72 hpi) related to the infection medium was determined by standard plaque assays. [+] indicates an increase of the virus titer from the infection medium, [0] virus titer at the same level as the infection medium, [−] virus titer below the infection medium.
  3. bVACV-mediated cell death was related to uninfected controls (24–72 hpi) and measured by MTT cell survival assays. [+] more than 50% of cells were killed by LIVP 1.1.1 [−] less than 50% of cells were killed by LIVP 1.1.1.